extended endocrine therapy: who will benefit?
Published 5 months ago • 51 plays • Length 6:35Download video MP4
Download video MP3
Similar videos
-
16:19
breast cancer index, extended endocrine therapy | elizabeth ott, pa | 2022 west oncology app updates
-
2:24
de-escalate patients who are unlikely to benefit from extended endocrine therapy
-
41:53
guideline updates for extended endocrine therapy decision-making in hr , early-stage breast cancer
-
5:04
standardizing extended endocrine therapy recommendations
-
0:35
how does breast cancer index help with patient selection for extended endocrine therapy?
-
10:02
breast cancer: extended adjuvant endocrine therapy
-
9:47
bci as a predictive biomarker for extended endocrine therapy benefit
-
1:50
challenges with patient selection for extended adjuvant endocrine therapy in breast cancer
-
0:51
breast cancer index is the modern tool to select patients for extended endocrine therapy
-
1:10:36
updates in extended endocrine therapy for hr breast cancer | asco21 & national practice guidelines
-
53:42
guideline updates for extended endocrine therapy decision-making in hr , early-stage breast cancer
-
38:22
adjuvant/neoadjuvant therapy for breast cancer: updates and molecular predictors of benefit
-
42:09
jadpro live 2023 - standardizing extended endocrine therapy decision-making
-
20:25
the predictive power of the breast cancer index (h/i) biomarker-sabcs 2022
-
3:16
what is breast cancer index?
-
6:09
adjuvant endocrine therapy for breast cancer: optimal durations and regimens
-
2:53
bci: guideline-recognized and validated to help guide extended endocrine decisions
-
20:13
endocrine treatment in breast cancer
-
2:38
understanding the abcsg trial and patient selection for extended endocrine therapy